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Abstract: While there have been many studies on health outcomes that have included 
measurements of plasma carotenoids, this data has not been reviewed and assembled into a 
useful form. In this review sixty-two studies of plasma carotenoids and health outcomes, 
mostly prospective cohort studies or population-based case-control studies, are analyzed 
together to establish a carotenoid health index. Five cutoff points are established across the 
percentiles of carotenoid concentrations in populations, from the tenth to ninetieth percentile. 
The cutoff points (mean ± standard error of the mean) are 1.11 ± 0.08, 1.47 ± 0.08,   
1.89 ± 0.08, 2.52 ± 0.13, and 3.07 ± 0.20 µM. For all cause mortality there seems to be a 
low threshold effect with protection above every cutoff point but the lowest. But for 
metabolic syndrome and cancer outcomes there tends to be significant positive health 
outcomes only above the higher cutoff points, perhaps as a triage effect. Based on this  
data a carotenoid health index is proposed with risk categories as follows: very high   
risk: <1 µM, high risk: 1–1.5 µM, moderate risk: 1.5–2.5 µM, low risk: 2.5–4 µM, and 
very low risk: >4 µM. Over 95 percent of the USA population falls into the moderate or 
high risk category of the carotenoid health index. 
Keywords:  β-carotene;  α-carotene; lycopene; zeaxanthin; β-cryptoxanthin; carotenoid; 
cancer; diabetes; cardiovascular disease 
 
1. Background 
In the scientific research community there has been a strong interest in the relationship between diet 
and health outcomes. Some initial results from case control studies, ecological studies, and population 
studies indicated that fruits and vegetables were strongly protective for cancer [1–3]. Later prospective 
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observational studies did not generally confirm the protective link between the intakes of fruits and 
vegetables and chronic diseases [4]. A significant portion of the differences in these two results might 
be the lack of accuracy in capturing dietary intakes by the use of the food frequency questionnaires 
(FFQ) in these very large studies. In fact, the FFQs have been called into question for their validity for 
vitamin C [5], dietary fat [6,7], and dietary fiber [8].  
A second problem may have been the selection of populations that had very few truly healthy 
individuals in them, that is, individuals in a state of complete physical, mental, and social well-being 
and not merely without disease or infirmity (WHO definition). In a few large, prospective cohorts the 
healthiest 3 percent, based on diet and lifestyle factors and some biochemical measures, were 
examined for risk of chronic diseases relative to the rest of the study population. In the Nurses’ Health 
Study there was a 91% reduced risk of diabetes in women [9], and an 82% reduced risk of coronary 
events [10]. In the men’s Health Professionals Follow-up Study there was a 71% reduced risk of colon 
cancer in this 3 percent healthy group [11]. In the Cardiovascular Health Study the healthiest 3 percent 
had an 89% reduction in risk of diabetes among men and women [12]. These decreased incidences of 
chronic disease are much greater than found in the reports that looked at quartiles or quintiles of fruits 
and vegetable intakes of the same cohorts [13,14]. Only in the small fraction of healthy people are 
great reductions of chronic disease found, so that looking at quartiles of intakes of fruits and vegetables 
is only comparing sick people with sicker people, not sick people versus healthy people. This 
comparison is an ineffective way to reveal what is required for healthy living.  
A third issue, one that is more fundamental, is that dietary intakes assume that all people absorb, 
assimilate, and metabolize the eaten food to the same degree and require the same amount of each 
nutrient to be healthy. The concept of biochemical individuality was brought to light by Roger 
Williams in 1956 and has been more completely explored with modern techniques since then [15]. 
However, biochemical and genetic individuality are completely neglected in large cohort studies.  
So, it can be stated that part of the failure of large cohort studies to confirm a positive link between 
the intake of fruits and vegetables and chronic disease is that largely unhealthy populations were 
queried with inaccurate FFQs and were assumed to be metabolically all the same. 
Perhaps a more fruitful method to search for an association between dietary intakes and chronic 
diseases is to look at plasma levels of bioactive substances. Such objective measurements are not 
subject to participant recall on a FFQ, or to pressure to conform to “healthy” expectations while filling 
out a dietary record. These measurements also account for some of the biochemical individuality of the 
subjects in a study. Measurement of a bioactive substance takes into account differences in absorption, 
assimilation, and metabolism of the substance, as well as varying amounts of the substances in the 
foods themselves. There are fewer metabolic estimates and no subjective recall in using plasma 
concentrations of bioactive substances. 
One of the most measured bioactive substances measured in a large number of population studies is 
total and individual carotenoids. While carotenoids have been widely shown to correlate with intakes of 
fruits and vegetables, the correlation coefficients between plasma carotenoids and fruit and vegetable 
intake were not very high, usually less than 0.5 [16–19], making carotenoids a less than stellar biomarker 
of fruit and vegetable intake. As mentioned above, differences in interindividual absorption, assimilation, 
and metabolism of carotenoids contribute to this problem. Nutrients 2011, 3  
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Is there a benefit to measuring plasma carotenoids apart from their use as a biomarker? In a recent 
study, Del Rio and coworkers found that by changing the total antioxidant capacity of the diet, while 
holding dietary intake of β-carotene constant, the concentration of plasma β-carotene could be doubled 
going from a low to high antioxidant diet [20]. Metabolic factors are involved, and the total antioxidant 
intake can influence the concentration of plasma carotenoids. It appears that there is information about 
the health of a person found in his or her plasma carotenoid concentration that goes beyond just a 
biomarker for fruit and vegetable intake.  
At this point there is enough evidence on health outcomes and plasma concentrations of carotenoids 
that guidelines can be proposed assigning health risk to various concentrations. It is important to note 
that the population studies of health outcomes do not support the use of dietary supplements to raise 
plasma carotenoids, but rather indicate that antioxidant-rich and carotenoid-rich foods should be eaten. 
2. Search Methodology and Analysis 
This review gathers together the data from many studies to establish a carotenoid health index based 
on blood levels. The studies are mainly prospective cohort studies, case-control studies nested within 
prospective cohorts, other case-control studies, and population-based cross-sectional studies that have 
measured plasma levels of carotenoids, especially total carotenoids, and health outcomes. This review 
is limited to human studies that include measurements of serum or plasma levels of carotenoids.  
This review will not go into the details of the health benefits that have been associated with upper 
concentrations of carotenoids in populations around the world. A spreadsheet summary of that 
information can be seen in additional file 1. A bibliography of all of the references is available in 
additional file 2. This html file contains the bibliographic metadata to import the reference data 
directly into bibliography software. 
Articles were searched for in PubMed under “carotenoids” AND “serum OR plasma” while limiting 
the search results to human studies. From identified studies and reviews, references were checked for 
any relevant studies that were missed, of which there were several. Searches were also performed for 
“carotenoids” and “diabetes” or “heart disease” or “cancer” to get specific studies, again limiting the 
results to human studies. 
One hundred and eleven studies were identified that associated plasma or serum carotenoids   
with health outcomes in people. Of these studies, sixty-two studies had published total carotenoid 
concentrations and/or concentrations of all six of the most prevalent individual carotenoids present in 
human blood. Concentration levels were published as means ± standard deviations, as geometric 
means with 25 and 75 percent levels or 5 and 95 percent levels, or as medians or cutoffs of tertiles, 
quartiles, or quintiles. 
In studies that only reported individual carotenoids, it is not possible to simply add medians of 
tertiles or quartiles to get the median for the total carotenoids. This method underestimates the lower 
end of the carotenoid range and overestimates the upper end. Even though the individual carotenoids 
are highly correlated, individuals that are low in one or two carotenoids are not necessarily low in all 
of the carotenoids. Likewise, individuals that are high in one carotenoid are not necessarily high in all 
of the carotenoids. To compensate for this, an estimate of the necessary adjustment was made from 
11 studies that reported total carotenoids as well as all of the individual carotenoids. To calculate the Nutrients 2011, 3  
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adjustment first the medians or means, as given, of the tertiles, quartiles, or quintiles for the individual 
carotenoids were summed together. Then these sums were compared to the reported medians or means, 
as given, of the total carotenoids. This percent difference was applied as an adjustment to similar sums 
of individual carotenoids in the twenty-three studies that only reported individual carotenoids and  
not total carotenoids. In Table 3 under the “Partitions Reported” column these studies are listed as 
reporting individual carotenoids with adjusted values. Studies that reported three partitions (means of 
tertiles or cutoff values for quartiles) were grouped together for the adjustment calculation. Likewise, 
studies with four values (means of quartiles or cutoff values for quintiles) were grouped together,  
and studies that reported means and standard deviations were grouped together. Table 1 gives the 
adjustment calculation for the seven studies that reported three partition values. The other calculations 
were done in similar manner. Table 2 demonstrates the adjustment applied to one study [21]. 
Table  1. Adjustment Calculation for Reporting Total Carotenoids from Individual 
Carotenoids. Percent difference between the sum of the individual carotenoids and reported 
total carotenoid values are given here for studies that gave three partition values. 
Reference Partition  Measure 
% Diff Cut 
1–2 
% Diff Cut 
2–3 
% Diff Cut 
3–4 
Akbaraly 2007 [22]  quartile cutoffs  23.5%  8.8%  −2.4% 
Epplein 2009 [23]  quartile cutoffs  13.5%  5.2%  −4.2% 
Epplein 2009 [24]  median tertiles  51.5%  26.6%  0.5% 
Goodman 1998 [25]  quartile cutoffs  5.6%  −1.9%  −11.2% 
Jenab 2006 [26]  quartile cutoffs  25.3%  12.9%  1.4% 
Shardell 2011 [27]  quartile cutoffs  14.8%  3.1%  −2.8% 
Yuan 2001 [28]  quartile cutoffs  17.0%  5.40%  1.1% 
Average Adjustment    +21.6%  +8.6%  −2.5% 
Table 2. Total Carotenoid Adjustment Applied to One Study, Dwyer 2004 [21]. 
Min  cut 1–2  cut 2–3  cut 3–4  cut 4–5  Max 
α-carotene  0.01 0.07 0.11 0.16 0.27 1.06 
β-carotene  0.02 0.24 0.42 0.64 1.05 8.00 
β-cryptoxanthin  0.01 0.05 0.06 0.08 0.12 0.60 
lutein  0.02 0.18 0.23 0.29 0.36 0.81 
zeaxanthin  0.01 0.04 0.05 0.06 0.09 0.28 
lycopene  0.03 0.31 0.47 0.67 1.03 6.47 
TOTAL,  SUM 0.10 0.89 1.34 1.90 2.92  17.22 
Adjustment +23%  +14%  +6%  −2% 
Adjusted  SUM    1.095  1.53 2.01 2.86 
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Table 3. Summary Data for the Carotenoid Health Index. 
First Author, Year 
Partition of Carotenoid 
Concentrations 
† 
Cutoff 
1 
Cutoff 
2 
Cutoff 
3 
Cutoff 
4 
Cutoff 
5 
Benefit, 
Fraction 
‡ 
Which  
carotenoids? 
§ 
Which 
sex? 
What outcome? 
Akbaraly 2009 [29] 
qnt cutoffs, men    1.61  2.3  2.9    yes, Qn2-5  total  men  all cause mortality 
qnt cutoffs, women    2.3  3.25  4.04    no  total  women  all cause mortality 
Bates 2011 [30] 
X  ± SD, men, calc. SD  0.636    1.15    1.664  yes  α-car, lut/zea  men  all cause mortality 
X  ± SD, women, calc. SD  0.687    1.299    1.911  no  all  women  all cause mortality 
deWaart 2001 [31]  90% range, men      0.99      yes  β-cryp, lut/zea  both  all cause mortality 
90%  range,  women    1.16    yes  β-cryp, lut/zea  both  all cause mortality 
Lauretani 2008 [32]  trt cutoffs, X  ± SD  1.11  1.466  1.8  1.971  2.49  yes, Qn2-5  total    all cause mortality 
Li 2010 [33]  qrt cutoffs, indiv, adj    0.883  1.297  1.649    yes, Qr2-4  α-car  both  all cause mortality 
Mayne 2004 [34]  X   ±  SD  0.58   1.29   2.00  yes  lyc,  α-car, total    all cause, CVD 
Ray 2006 [35]  qrt median, min, max    1.038  1.452  1.995    yes, Qr2-4  total  women  all cause mortality 
Sahyoun 1996 [36] 
X  ± SD, men  1.48  1.7  2.39  3.08  3.3 
yes, T2-3 
total  both  all cause mortality 
X  ± SD, women  1.56  1.7  2.53  3.08  3.5       
Shardell 2011 [27]  qrt cutoffs, indiv carot, total    1.01  1.33  1.75    yes, Qr2-4  total, α-car, lyc  both  all cause mortality 
Akbaraly 2007 [22]  qrt cutoffs   1.16  1.65  2.35   yes  lyc,  lut/zea  both cognition 
Alipanah 2009 [37]  X   ±  SD  1.13   2.09   3.03  yes  total  women  walking  speed 
Yang 2008 [38]  X  ± SD, women, 5–95%  1.87    4.22    6.57  no    women  osteoporosis 
D’Odorico 2000 [39] 
X  ± SD, men, indiv carot, adj  1.17    1.98    2.79 
yes, Qn5 
α-car, β-car both  atheroscl.  lesions 
X  ± SD, women, indiv carot, adj  1.46    2.78    4.1       
Dwyer 2004 [21]  qnt cutoffs, indiv carot, adj    1.313  2.014 2.86  yes  lut,  zea,  β-crypt, α-car both  intima-media  thick. 
Hak 2003 [40]  qnt medians, indiv carot, adj  1.117  1.44  1.694  2.051  2.856  no    men  2nd myo. infarction 
Hozawa 2009 [41]  qrt cutoffs, total-lyc    1.08  1.29  1.57    yes, Qr4  total w/o lyc  both  hypertension 
Hozawa 2007 [42]  qrt medians, cutoffs  0.829  1.056  1.357  1.59  1.99  yes  total w/o lyc  both  inflamm. measures 
Beydoun 2011 [43]  qrt cutoffs, ranges, total    0.863  1.183  1.622    yes, Qr3-4  total  both  metabolic syndrome 
Sugiura 2008 [44]  trt cutoffs, ranges, indiv, adj    2.99    4.85    yes, T3  β-car, β-crypt both  metabolic  syndrome 
Suzuki 2011 [45] 
g.mean, 25, 75% indiv, adj men    2.054  2.728  3.42    yes, T3  β-crypt, β-car men  metabolic  syndrome 
g.mean, 25, 75% indiv, adj 
women 
 3.078  4.081  5.16   yes  β-crypt, β-car, α-car women  metabolic  syndrome 
Ford 2003 [46]  qrt cutoffs, indiv, adj  0.883  1.297  1.649  yes, Qr2-4  all 5 indiv.  both  high CRP 
Hughes 2009 [47]  median, 25, 75%, indiv & total  0.63  0.92  1.51  no  both  isoprostanes Nutrients 2011, 3  
 
 
1008
Table 3. Cont. 
Akbaraly 2008 [48]  qrt cutoffs, total  1.82  2.55  3.43  yes, Q4  total  both  dysglycemia 
Coyne 2005 [49]  qnt medians, indiv, adjusted  0.8  1.39  1.93  2.53  4.09  yes  all 5 indiv.  both  fast glucose, OGTT 
Hozawa 2006 [50]  qrt cutoffs, ranges  0.98  1.29  1.66  yes  total  both  diabetes 
Suzuki 2002 [51]  trt cutoffs, indiv, adj  3.14  5.03  yes  all 5 indiv.  both  high Hb1Ac 
Wang 2006 [52]  qrt medians, indiv, adj  0.619  1.32  1.77  2.602  no  all 5 indiv.  women  diabetes 
Connett 1989 [53] 
X  ± SD, total, β-car, cases  0.925  1.59  2.25 
yes, Qn4-5 
total, β-car both  lung  cancer 
X  ± SD, total, β-car, controls  1.05  1.81  2.57 
Epplein 2009 [23]  trt medians, total & indiv  1.67  2.53  3.72  yes, T2-3  total, all 5 indiv.  men  lung cancer 
Ito 2003 [54] 
g.mean, 5–95th%, cases  1.74 
yes, Qr2-4 
total, α-car, β-car, lyc, crypt  both  lung cancer 
g.mean, 5–95th%, controls  1.87 
Ito 2005 [55] 
qrt cutoffs, men  1.22  1.69  2.53  yes, Qr4  α-car, β-car, lyc, crypt  men  lung cancer 
qrt cutoffs, women  1.87  2.76  3.93  no  women  lung cancer 
Yuan 2001 [28]  qrt cutoffs, total & indiv.  0.743  0.941  1.222  yes, Qr3-4  β-crypt, total (smokers)  men  lung cancer 
Dorjgochoo [56] 
qrt cutoffs, cases  1.89  2.43  2.99 
no 
none women  breast  cancer 
qrt cutoffs, controls  1.86  2.21  2.86  women 
Epplein 2009 [23]  qrt cutoffs, total & indiv.  2.072  2.771  3.583  no  none  women  breast cancer 
Ito 1999 [57] 
X  ± SD, cases  0.513  0.847  1.181 
yes 
all 5 indiv.& total  women  breast cancer 
X  ± SD, controls  0.655  1.181  1.707  women 
Kabat 2009 [58]  trt cutoffs, indiv, adj  1.65  2.4  yes, T3  α-car women  breast  cancer 
Maillard 2010 [59]  X  ± SD, controls  1.39  2.19  2.99  no  none  women  breast cancer 
Rock 2005 [60]  qrt cutoffs, medians, total  1.038  1.537  2.182  2.867  4.189  yes, Qr4  total  women  breast cancer 
Rock 2009 [61]  trt cutoffs, total  1.656  2.452  yes, T2-3  total  women  breast cancer 
Sato 2002 [62]  qnt cutoffs, total & indiv  1.131  1.683  2.231  yes, Qn5  β-car, lyc  women  breast cancer 
Tamimi 2005 [63]  qnt medians, total & indiv  1.01  1.48  1.85  2.27  3.05  yes, Qn5  α-car, β-car, lut/zea, total  women  breast cancer 
Toniolo 2001 [64] 
X  ± SD, cases  1.438  2.306  3.174 
yes, Qr2-4 
β-car, lut, cryp, total  women  breast cancer 
X  ± SD, controls  1.527  2.593  3.659  women 
Chang 2005 [65] 
qrt cutoffs, total, cases  0.82  1.18  1.45 
yes 
α-car, β-car, β-cryp, lut/zea,  men  prostate cancer 
qrt cutoffs, total, control  0.88  1.14  1.63  men 
Gill 2009 [66]  qrt medians, total & indiv  1.842  2.552  3.31  4.712  no  none  men  prostate cancer 
Goodman 2003 [67]  qrt cutoffs, indiv, adj 1.076  1.466  1.856  yes, Qr3-4  lut, zea, β-crypt both  lung/prostate  cancer Nutrients 2011, 3  
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Huang 2003 [68]  qnt cutoffs, indiv, adj  1.030  1.476  1.91  no  none  men  prostate cancer 
Key 2007 [69]  qnt cutoffs, lyc & total 
 
1.27 1.82 2.32 
 
yes, Qr4  lyc, total  men 
prostate cancer, esp. 
advanced 
Lu 2001 [70]  qrt cutoffs, indiv, adj  0.602 0.832 1.222  yes,  Q3-4  lyc, zea, lut, β-crypt men  prostate  cancer 
Peters 2007 [71]  qnt medians, indiv, adj  1.233  1.777  2.225  2.708  3.843  no   lyc, β-car men  prostate  cancer 
Vogt 2002 [72]  qrt cutoffs, min, max, indiv, adj 
 
0.879 1.285 1.745 
 
yes, Q4  lyc  men 
prostate cancer, esp. 
advanced 
Zhang 2007 [73]  qrt medians, indiv, adj  0.673  1.064  1.444  2.218  yes, Q4  lyc  men  prostate cancer 
Jiang 2005 [74] 
qrt cutoffs, men  1.36  1.92  2.5  yes, Q4  α-car, β-car, total  men  colorectal cancer 
qrt  cutoffs,  women  1.91 2.64 3.06  no  all  women  colorectal  cancer 
Steck-Scott 2004 [75]  qrt medians, total & indiv  0.972  1.376  1.78  2.495  yes, Q4  α-car, β-car, total  both  polyps in colon 
Wakai 2005 [76] 
trt medians, men, total & indiv  1.48  1.59  2.21  yes, T2-3  total  men  colorectal cancer 
trt medians, women, total & indiv,  2.06  2.55  2.96  no  α-car, total  women  colorectal cancer 
Jenab 2006 [26]  qrt cutoffs, total & indiv  1.294  1.811  2.494  yes, Qr4  β-cryp, zea, total  both  gastric cancer 
Persson 2008 [77]  qrt cutoffs, medians, indiv, adj  0.668  1.109  1.723  2.274  2.932  yes, Qr3-4  α-car, β-car men  gastric  cancer 
Yuan 2004 [78]  qrt cutoffs, indiv, adj  0.571  0.818  1.138  yes, Qr4  α-car, β-car, lyc  men  gastric cancer 
Goodman 1998 [25]  qrt cutoffs, total & indiv.  1.71  2.183  2.826  yes, Qr3-4  crypt, total  women  cervical dysplasia 
Nagata 1999 [79]  trt medians, indiv, adj  2.357  3.518  5.707  yes, T2-3  α-car, lyc  women  cervical dysplasia 
Schiff 2001 [80]  trt cutoffs, indiv, adj    2.141    2.728    yes, T3  α-car, β-crypt, lut/zea  women  cervical dysplasia 
Nomura 1997 [81] 
X  ± SD, cases  0.713 
 
1.521 
 
2.329 
yes, T2-3 
α-car, β-car, β-crypt, 
total 
men 
upper aerodigestive 
tract cancer 
X  ± SD, controls  0.955  1.774  2.593  men 
Delcourt 2006 [82]  trt cutoffs, indiv, adj 
 
1.119 
 
3.085 
 
yes, T2-3  zea, lut, α-car both 
age-related 
maculopathy, cataract 
† qnt = quintile, qrt = quartile, trt = tertile,  X  = arithmetic mean, SD = standard deviation, adj = individual carotenoids summed and adjusted to better fit total carotenoid 
approximations; 
‡ Qn = quintile, Qr = quartile, T = tertile. The quartiles with statistically different outcomes compared to the lowest partition are listed;   
§ α-car = α-carotene, β-car = β-carotene, lut = lutein, zea = zeaxanthin, lyc = lycopene. 
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3. Summary of Studies 
Table 3 lists the sixty-two studies that reported complete information on carotenoid concentrations 
and health outcomes. The studies are listed alphabetically within categories of health outcomes. The 
divisions of the partitions are listed. To aid in establishing cutoff points, the percentiles of the carotenoid 
concentrations within study populations are grouped together in five levels from percentiles 10–18,   
20–40, 50–62.5, 66–80, and 84–90. Any values below the tenth percentile or above the ninetieth 
percentile were not included in the calculations for establishing cutoff points. These values are 
descriptive, but were not used in assigning risk of disease. Only eleven studies included this information. 
The minimum and maximum concentrations for cutoff point 1 are 0.513 and 2.36 µM, respectively. 
In the upper level, cutoff point 5, the minimum and maximum are 1.181 and 6.57 µM. 
There are nine studies that reported all cause mortality as the principal endpoint, five with 
cardiovascular endpoints, three with metabolic syndrome endpoints, two with inflammation or lipid 
peroxidation endpoints, five with diabetic endpoints, five with lung cancer, ten with breast cancer, nine 
with prostate cancer, three with colorectal endpoints, three with gastric cancer, three with cervical 
dysplasia, one with upper aerodigestive tract cancer, and one study with age-related maculopathy and 
cataract endpoints. 
Table 4 lists the cutoff points across the percentiles of carotenoid concentrations. For all sixty-two 
studies the cutoff points (±standard error of the mean) are 1.11 ± 0.08, 1.47 ± 0.08, 1.89 ± 0.08,  
2.52 ± 0.13, and 3.07 ± 0.20 µM. There are ten case-control studies included in the analysis, with 
health outcomes measured across the range of carotenoids within the participants. The averages across 
the levels did not change significantly, only in the third significant figure, when these case-control 
studies were excluded. There were 21 measurements of just men and 28 measures of just women. 
Across all partitions the women have higher concentrations of plasma carotenoids than men, ranging 
from about 0.15 µM higher at the lower end to more than 0.6 µM higher at cutoff points 3 and 4. There 
appears to be an international difference in carotenoid concentrations in men and women, most likely 
due to different gender-based dietary intakes around the world. 
Table 4. Summary of Data for the Carotenoid Health Index. 
Averages across Percentiles, µM 
Cutoff 1  Cutoff 2  Cutoff 3  Cutoff 4  Cutoff 5 
10–18% 20–40%  50–62.5% 66–80%  84–90% 
All Studies, N = 62  1.114  1.468  1.893  2.522  3.069 
SEM 
‡ 0.078  0.079  0.085  0.129  0.204 
Men Only, N = 21  1.091  1.359  1.735  2.263  2.923 
Women Only, N = 28  1.237  1.800  2.336  3.025  3.411 
No Benefit studies, N = 10  1.251  1.747  2.357  2.873  3.641 
Benefit Studies, N = 52  1.123  1.463  1.874  3.012  3.679 
Carotenoid Health Index, µM  <1  1 to <1.5  1.5 to <2.5  2.5 to <4  ≥4 
 
Very High 
Risk 
High 
Risk 
Moderate 
Risk 
Low Risk 
Very Low 
Risk 
 
‡ SEM = Standard Error of the Mean. Number of data points for the cutoff points are 32, 56, 72, 52, 
and 32 for cutoffs 1 to 5, respectively. Nutrients 2011, 3  
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Within the sixty-two studies there are 52 that reported a benefit. Some studies had benefits for total 
carotenoids and three or four individual carotenoids, while others only found a significant effect from 
one individual carotenoid and even only in a sub-group of the study (men, or just non-smokers, or just 
advanced prostate cancer), as shown in Table 3. A comparison of the average carotenoid concentration 
at each cutoff point is given in Table 4. The studies with benefits had a slightly lower bottom cutoff, 
but the upper cutoff was about the same. Cutoff points 2 and 3 were substantially higher on average in 
the studies with no benefits, indicating that the populations in the no-benefit studies probably had 
concentrations that were skewed further to the right, though the highs and lows were not all that 
different. This might be part of the reason that some benefit was found in some studies but not in 
others. There may be publication bias towards positive studies in the literature, but an attempt were 
made within this review to ensure that studies were not excluded or included based on whether or not a 
benefit was found. 
4. Threshold, Dose-Response, or Triage Mechanism 
One major question regarding carotenoids is whether there is a threshold effect, or whether there is 
a continuous dose-response effect up through at least the concentrations commonly seen in 
populations. Within these sixty-two studies there were 40 that had multivariate regression models that 
gave odds ratios across the range of carotenoids within the study populations (see Table 3, Benefit, 
Fraction column). From these models it is apparent which fractions of the population are significantly 
different from the reference fraction, usually the lowest fraction. So, of these 40 studies there were  
24 studies in which only the top tertile or top one or two quartiles or quintiles had a statistically 
different positive health outcome from the lowest reference fraction. There were 16 studies in which 
only the lowest fraction had a statistically different health outcome from the rest of the population. 
Whether there is a threshold or dose-response may depend on the particular outcome. In all of the 
studies that reported all-cause mortality only the lowest partition of the population seemed to be at risk 
due to low levels of carotenoids. There seemed to be a threshold for this particular outcome. However, 
for metabolic syndrome or dysglycemia only the upper tertile or top two quartiles had a significant 
benefit compared to the lowest tertile or quartile. For cancer outcomes the results are mixed, but 
overall favor a significant benefit only in the upper concentrations of carotenoids. 
Perhaps there is a triage effect for carotenoids, as proposed for other nutrients by Bruce Ames. 
McCann and Ames demonstrated such an effect for vitamin K [83]. The triage concept is that nutrients 
will go to the systems of the body that are most critical for short-term survival first. Then if there is a 
sufficient quantity of the micronutrient all of the other systems of the body will also receive a 
beneficial amount to prevent subtler dysfunction and age-related disease. The amounts of carotenoids 
needed to avoid mortality from any cause may be less than the amount to help prevent dysglycemia, 
diabetes, and some forms of cancer. 
The mechanism or mechanisms by which the triage effect might take place with carotenoids is not 
certain. However, it is known that carotenoids have functions beyond their antioxidant properties.  
In vitro studies with AGS gastric cells showed that β-carotene and lutein both showed   
anti-inflammatory action. Not only did β-carotene and lutein cause a reduction in the levels of reactive 
oxygen species when the gastric cells were exposed to H2O2, indicating antioxidant activity, but there Nutrients 2011, 3  
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was also an inhibition of the activation of NF-κB and the subsequent expression of IL-8, indicating 
anti-inflammatory activity [84]. In a study of preterm infants supplemented with β-carotene, lutein, 
and lycopene compared to unsupplemented preterm infants and full-term infants fed human milk, 
Rubin and coworkers [85] found that the supplemented infants had decreased concentrations of   
C-reactive protein, a marker of systemic inflammation. The supplemented group also had greater   
rod photoreceptor sensitivity, indicating that lutein had protective effects for the retina of pre-term 
infants as well. More beneficial effects of lutein for retinal health were found in a mouse model of 
endotoxin-induced uveitis. Along with a reduction in reactive oxygen species in the retina neural cells, 
the negative effects of inflammation (a decrease in rhodopsin expression, shortening of outer segments 
of outer photoreceptor cells, levels of STAT3 activation and downstream inflammatory cytokines), 
were all prevented by lutein treatment given before and concurrently with the endotoxin to induce 
inflammation in the mice [86]. Together these studies indicate that carotenoids can suppress the 
inflammatory cascade and normalize cellular function. 
Carotenoids have been shown to have specific anti-cancer properties as well. Lycopene induced 
apoptosis in LNCaP human prostate cancer cells at 0.3 to 3.0 µmol/L [87] or at 1 and 5 µmol/L [88]. 
Kotake-Nara and coworkers [89] studied the effect of 15 different carotenoids on the growth of three 
different prostate cancer cell lines. At 20 µmol/L neoxanthin from spinach and fucoxanthin from brown 
algae decreased cell viability at least 85% in all three cell lines via apoptotic mechanisms. Significant 
effects were also seen for phytofluene, ζ-carotene, and lycopene. Lycopene, and to a smaller extent  
β-carotene, enhanced gap junction communication in KB-1 cells derived from human oral cancer [90]. In 
10T1/2 cells Zhang and coworkers [91] found that β-carotene, canthaxanthin, lutein, lycopene, and  
α-carotene all increased gap junctional communication, which was not correlated with the carotenoids’ 
pro-vitamin A activity or ability to quench lipid peroxidation. Physiological concentrations of   
β-carotene inhibited cell growth in several human colon adenocarcinoma cell lines by inducing cell 
cycle arrest in G2/M phase and apoptosis [92]. Palozza and coworkers [93] also found that tomatoes 
digested in vitro were able to stop the growth of colon adenocarcinoma cell lines HT-29 and HCT-116 
and induce apoptosis. Similar results were also seen in tomatoes genetically modified to express large 
amounts of β-carotene [94]. Induction of apoptosis by β-carotene via the caveolin-1 pathway, an 
intracellular signaling pathway usually deregulated in cancer cells, showed yet another mechanism for 
carotenoids to act [95]. Carotenoids also have antimetastatic activity. Lycopene inhibited adhesion, 
migration, and invasion of SK-Hep1 human hepatoma cells [96]. In vivo inhibition of metastasis was 
shown in a follow-up study by injecting SK-Hep1 cells into athymic nude mice that had been treated 
for two weeks with placebo or lycopene or β-carotene. Mice treated with lycopene or β-carotene had 
significantly reduced numbers of metastasized tumors in the lungs, and smaller cross-sectional area of 
the tumors [97]. Lycopene, but not β-carotene, also decreased the positive rate of proliferating cellular 
nuclear antigen (PCNA), the concentration of vascular endothelial growth factor (VEGF), and protein 
expressions of PCNA, and MMP-9 (matrix metalloproteinase-9) in lung tissue. 
Nutragenomic research using microarrays found that lycopene modulated the expression of 391 genes 
in estrogen-positive breast cancer cells, but not in estrogen-negative breast cancer cells or fibrocystic 
breast cells [98]. Genetic pathways affected included apoptosis, cell communication, MAPK and cell 
cycle, xenobiotic metabolism, fatty acid biosynthesis and gap junctional communication. Nutrients 2011, 3  
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There are so many pathways that respond to carotenoids that it is quite possible that a triage 
mechanism is present. Some molecular switches may be inhibited or activated at low concentrations of 
certain carotenoids while other pathways are abnormally active until the concentrations are much 
higher. It is unlikely that all cellular pathways are equally affected at the same concentration of 
carotenoids. So, while there may seem to be a threshold above which some outcomes are not affected, 
it is much more likely that there are molecular pathways and systems in the body that would benefit 
from higher plasma levels of carotenoids.  
5. Protective Concentration of Total Carotenoids 
In Table 4 the proposed Carotenoid Health Index is given. This index is based on the cutoff points 
of carotenoid concentrations associated with the health outcomes in the sixty-two studies reviewed 
here. The category most strongly associated with negative health outcomes is less than 1 µM. This 
category is associated with the lowest quartile or quintile in most population-based studies. In the 
intermediate range there is some protection, with increasing amounts as the concentration is increased. 
Category 4, from 2.5 to 4 µM is associated with positive health outcomes in many studies. This 
amount is greater than the 90th percentile of the USA population in a recent survey [99]. 
There is a higher category, greater than 4 µM, which may be associated with even greater health 
benefits. Five of the sixty-two studies had upper partitions of the study population in this range (see 
Table 3, Cutoff 4 and 5 columns). It isn’t clear exactly where the cutoff should be for this upper range 
to indicate where the greatest health benefits begin. It could be 5 µM or 3.5 µM rather than 4 µM. 
There is not a lot of evidence at these higher levels of plasma carotenoids because these high levels are 
not frequently found in the general population. However, among sub-groups that consume very large 
amounts of fruits, vegetables, especially leafy greens, and vegetable juice, there may be health benefits 
associated with high levels of carotenoids. Self-reported health outcomes from people following 
programs like the Hallelujah Diet, though anecdotal in nature, seem to indicate some benefits from 
such high intakes of colorful plant foods. 
One limitation of The Carotenoid Health Index is that it is limited to people who do not have a 
chronic thyroid, liver, or kidney disease which causes carotenemia. Though high plasma carotenoid 
levels are usually due to high dietary intakes and a high overall total antioxidant intake [20], it is 
possible that a disease process itself might cause abnormally high levels of carotenoids in the plasma 
as well as in the skin [100].  
It is an assumption here in this review that when concentrations of total carotenoids are at a 
protective level, the individual levels will also be at protective levels. In the intermediate range there 
may be some protection from just one carotenoid or another, but at a sufficiently high range of total 
carotenoids there should be protective amounts of all of the individual carotenoids. So, if the total 
carotenoid level is targeted then all of the individual carotenoids will follow. (The only exception to 
this may be lycopene and astaxanthin that occur in only a few foods.) From a public health standpoint, 
the main message is to eat a variety of antioxidant-rich and carotenoid-rich fruit and vegetables   
(not just tomatoes or carrots) to increase the total carotenoids to a concentration that will include 
protective concentrations of the individual carotenoids. Nutrients 2011, 3  
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6. Implications of the Carotenoid Health Index 
If a low risk category of total plasma carotenoids is greater than 2.5 µM, as the evidence from these 
62 studies seems to indicate, and a very low risk category above 4 µM, what are the implications for 
public health policy? First, having an absolute standard for carotenoid concentrations will help guide 
future research and interpretation of measurements of carotenoids in populations. Knowing how a 
study population compares to other populations is critical to understanding why health goals have or 
haven’t been achieved. The carotenoid health index assists in this interpretation. 
A second implication is that the carotenoids health index gives a reference for intervention studies 
to aim for achieving. If a dietary pattern or a food raises the total carotenoid concentration up to a 
protective level, then it is more likely to result in positive health outcomes, though this has not yet been 
proven in randomized controlled trials. If a proposed dietary pattern does not raise the total plasma 
carotenoid concentration to a protective level, it gives some insights into perhaps why the study did not 
yield very positive results. The carotenoid health index provides an objective standard to help 
researchers and scientists design successful trials. The carotenoid health index also gives researchers 
sufficient scientific justification for applying for research funds for trials that may seem extreme, but will 
actually raise plasma carotenoid concentrations to protective concentrations, hopefully leading to more 
positive study results.  
Third, if this review is correct in its assessment of the scientific literature, the carotenoid health 
index indicates that essentially the entire population of the USA and most of the populations of other 
countries do not have protective concentrations of plasma carotenoids. More research should be done 
to demonstrate the most effective ways to improve this measurement. It will most likely include more 
carotenoid-rich foods, but it may also require replacing junk food and sugary foods and beverages with 
highly nutritious foods, even foods not high in carotenoids. The total antioxidant capacity of the entire 
diet needs to be raised to fully utilize the carotenoids that are being eaten [20]. This should be a much 
higher national priority for all countries that wish to improve the health and productivity of their 
citizens and to overcome the burden of rising health care costs associated with chronic diseases.  
There are dietary supplements containing mixed carotenoids that will boost a person’s plasma 
carotenoid concentration. However, the studies summarized here did not use such dietary supplements, 
so there is very little scientific support for the use of dietary supplements of carotenoids to improve 
health outcomes. It is true that carotenoids are bioactive compounds, but there are many other 
compounds in fruits and vegetables that are also beneficial and should be included in the diet. Though 
unscrupulous marketers may use the carotenoid health index for selling dietary supplements, 
responsible scientists and food producers need to emphasize the use of foods and whole food   
products to improve plasma carotenoid concentrations. We have painfully learned that just adding a  
β-carotene supplement to one’s diet will increase the risk of lung cancer in smokers [101]. Such 
mistakes should not be repeated. 
7. Conclusions 
The Carotenoid Health Index gives researchers and scientists an objective tool that encompasses the 
vast literature on plasma carotenoids and health outcomes. From planning clinical trials to evaluating Nutrients 2011, 3  
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study results, this index gives them a tool for understanding one of their objectives. Rather than just 
looking at increasing servings of fruits and vegetables, scientists can aim for a biological response that 
can vary considerably between different individuals even when eating identical diets. However, while 
more research is being conducted, public health policy has clear evidence that the lack of vegetables in 
the modern diet is the most important flaw on the dining table, and the carotenoid health index points out 
this flaw with unwavering clarity. If the intake, absorption, assimilation, and metabolism of fruits and 
vegetables was such that the tenth percentile of plasma total carotenoids, rather than the ninety-fifth 
percentile, was near 2.5 µM in the USA and every other nation, then there would be a vast improvement 
in health and productivity. 
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